Teva Reshuffles Top Management
North America Commercial Head Brendan O’Grady Moves On
Executive Summary
Teva has announced a major management reshuffle that will see North America commercial vice-president Brendan O’Grady leave the company for a new role outside the pharmaceutical industry. Revealing his replacement, Teva also unveiled further changes.
You may also be interested in...
Teva Looks To Novartis To Replace Departing Dethlefs
Teva’s commercial interests in North America will soon be under new leadership after the firm announced that Sven Dethlefs would leave the company in mid-November. The firm has looked to the branded sector for his replacement.
Is Teva’s US Decline In Q3 Evidence Of A Broader Downward Trend?
Teva faced questions about the current environment in the US for generics, following weakness in its numbers and in those of rival Sandoz during the third quarter. Management remains “very committed to the US generics segment,” after sales dropped by 7%.
What’s Next? Five Things To Look Out For In August
In the month ahead, Teva will see a key management change, Polpharma is set to wrap up a landmark Phase III biosimilar study and financial results for all manner of industry participants will continue to trickle out.